Aslıhan Baran

Aslıhan Baran

Auto-generated profile, based on publicly available information

Aslıhan Baran

Department of Neurology, Yüksek İhtisas University, Medicalpark Hospital, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2023 in European journal of pain
Verified
Journal Article
Open access
HKH. Altmis Kacar
H. Altmis Kacar
COC. Ozkul
C. Ozkul
ABA. Baran
A. Baran
AGA. Guclu‐Gunduz
A. Guclu‐Gunduz
Background: This study aimed to investigate the effects of Cervical Stabilization Training (CST) on the headache, neck pain and cervical musculoskeletal system in patients with headache compared to the control group.Methods: A total of 90 female patients with migraine, tension‐type headache and cervicogenic headache (CGH) participated in this study. The patients were divided into the cervical stabilization training group (CSTG) and the control group (CG). The CSTG performed the CST three times a week for 8 weeks while the CG continued their ongoing medical treatment. The pain intensity was assessed by Visual Analogue Scale, forward head posture by craniovertebral angle measurement, the endurance of deep cervical flexor muscles by craniocervical flexion test and the endurance of cervical muscles by flexor and extensor endurance tests before and after 8 weeks. In addition, disability levels, health‐related quality of life, sleep quality and mood were assessed by the Migraine Disability Assessment questionnaire, Neck Disability Index (NDI), Short Form 36 Quality of Life Scale, the Pittsburgh Sleep Quality Index and Beck Depression Scale, respectively.Results: Headache frequency, duration and intensity, neck pain intensity and forward head posture reduced while activation and performance of deep cervical flexor muscles, the endurance of cervical flexor and extensor muscles increased in the CSTG (p < 0.05). Furthermore, the disability levels, quality of life, sleep quality and mood also improved in the CSTG (p < 0.05).Conclusions: This study suggests that CST reduces headaches and neck pain by improving the cervical musculoskeletal system in patients with headache.Significance: The CST improved the headache frequency, duration and intensity, neck pain intensity, cervical posture, activation of deep cervical flexor muscles and endurance of cervical muscles in patients with headache. In addition, improvements in the cervical musculoskeletal system contributed to a reduction in the intensity of headaches and neck pain. Therefore, CST may be preferred in the treatment of headaches, especially with coexisting neck pain.

14 October 2022
Verified
Book Chapter
Closed access
ABAslıhan Baran
Aslıhan Baran
FAFERİT ASLAN
FERİT ASLAN
Paraneoplastik sendromlar, kanserin doğrudan invazyonu veya metastazı dışında, malign ve normal dokular arasındaki immün çapraz reaksiyonlar veya humoral faktörler nedeniyle uzaktan ortaya çıkan sistemik bozukluklardır. En sık nörolojik sistemleri etkileyen bu sendromlar (PNS), vakaların %80'inde kanser tanısı konmadan önce saptanmaktadır. Bu durum, gizli tümörlerin erken evrede teşhis edilmesine olanak tanır. 2021 yılında PNS-Care paneli, PNS bağlamında antikorları kanser birlikteliği sıklığına göre üç gruba ayırmıştır: Kanser ilişkisi %70'ten fazla olan "Yüksek Riskli Antikorlar" (Hu, Yo, Ri, CV2/CRMP5, SOX1, PCA2, Amfifizin, Ma2/Ma, Tr, KLHL11); hücre içi antijenleri hedefler ve sitotoksik T hücre aracılı patogeneze sahiptir. Kanser ilişkisi %30-70 arasında olan "Orta Riskli Antikorlar" (AMPAR, GABABR, mGluR5, NMDAR, CASPR2, P/Q VGCC) ise hücre yüzeyi veya sinaptik proteinleri hedefleyerek doğrudan antikor aracılı mekanizmalarla çalışır. Üçüncü grup ise %30'dan az kanser ilişkisi gösteren düşük riskli gruptur. Tanı aşamasında serum ve BOS testlerinin birlikte yapılması önerilir. Pozitif yüksek riskli antikor saptandığında, ilk tarama negatif olsa bile tümör taramalarının 2 yıl boyunca 4-6 ayda bir tekrarlanması kritik önem taşır. Paraneoplastic syndromes are systemic disorders caused by humoral factors or immune cross-reactivity between malignant and normal tissues, occurring remote from the primary tumor or metastasis. Most frequently inducing neurological manifestations, paraneoplastic neurological syndromes (PNS) are detected before a cancer diagnosis in 80% of cases, enabling the early identification of occult malignancies. In 2021, the PNS-Care panel updated the diagnostic criteria and classified onconeuronal antibodies into three risk categories based on their cancer association frequency. "High-Risk Antibodies" (>70% cancer-associated), such as Hu, Yo, Ri, and CV2/CRMP5, typically target intracellular antigens and are mediated by cytotoxic T-cell mechanisms. Conversely, "Intermediate-Risk Antibodies" (30%-70% cancer-associated), including NMDAR, AMPAR, GABABR, and P/Q VGCC, target cell surface or synaptic proteins, driving directly pathogenic antibody-mediated responses. "Low-Risk Antibodies" exhibit less than a 30% correlation with underlying malignancies. For robust diagnosis, concurrent testing of both serum and cerebrospinal fluid (CSF) is highly recommended. Clinically, identifying high-risk antibodies necessitates rigorous tumor screening every 4 to 6 months for a duration of 2 years, even if initial oncological screenings yield negative results.

22 July 2026 in BMC Neurology
Verified
Journal Article
Open access
PDF file
ABAslıhan Baran
Aslıhan Baran
White matter hyperintensities (WMH) are increasingly recognized as imaging markers of migraine-related cerebral small-vessel injury. However, the biologica

14 October 2022
Verified
Book
Open access
PDF file
MUMehmet Uzun
Mehmet Uzun
IUİrEm Uğurlu
İrEm Uğurlu
ABAslıhan Baran
Aslıhan Baran
FAFERİT ASLAN
FERİT ASLAN
MÖMelike Özçelik
Melike Özçelik
MPMetin Pehlivan
Metin Pehlivan

28 August 2026 in Turkish Journal Of Neurology
Verified
Journal Article
Open access
PDF file
ŞAŞeref Barbaros Arik
Şeref Barbaros Arik
MSMurat Simsek
Murat Simsek
ABAslıhan Baran
Aslıhan Baran
GŞGökhan Şahin
Gökhan Şahin
Objectives: This study aimed to evaluate the diagnostic performance of an artificial intelligence (AI)-based decision support model that estimates the probability of dementia using only routine fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) sequences and to assess its potential role as a triage tool in outpatient clinical settings. Patients and methods: This retrospective single-center study included 96 patients who underwent brain MRI and had established clinical and neuropsychological diagnoses between January 2021 and December 2024. A previously published convolutional neural network model trained on 6,400 open-access MRI scans was applied to our institutional dataset to evaluate its diagnostic performance in a real-world clinical setting. For clinical interpretability, a predefined threshold of 50% was used to classify cases, and receiver operating characteristic analysis was performed to assess discriminative performance. Results: The dementia group (n = 47) had a mean age of 71.76 ± 8.32 years (range, 55 to 90 years) and included 25 females (53.2%) and 22 males (46.8%). The control (nondementia) group (n = 49) had mean age of 75.18 ± 7.48 years (range, 55 to 89 years) and included 25 females (51.0%) and 24 males (49.0%). The AI model achieved an accuracy of 89.6%, sensitivity of 78.7%, specificity of 100%, and an AUC of 0.937. The dementia probability (%) strongly correlated with clinical diagnoses (r = 0.762, p < 0.001). Notably, no false-positive cases were observed in this cohort, indicating high reliability of positive classifications. McNemar and Binomial tests confirmed that the classification performance was significantly better than chance ( p < 0.001). Conclusion: Artificial intelligence-derived dementia probability from routine FLAIR MRI provides a rapid and standardized output that may support clinical decision-making at the initial point of care. The absence of false-positive cases is consistent with the potential utility of the model as a rule-in decision-support tool, supporting prioritization of patients for further diagnostic evaluation. These findings highlight the potential of a simple, single-sequence AI approach to enhance workflow efficiency in neuroradiology practice without replacing clinical judgment.

30 January 2026 in Journal Of Clinical Neurophysiology
Verified
Journal Article
Closed access
ABAslıhan Baran
Aslıhan Baran
OGOnur Serdar Gençler
Onur Serdar Gençler
SASerhat Akın
Serhat Akın
Purpose: This study aimed to assess the diagnostic utility of the medial dorsal cutaneous (MDC) nerve and the medial dorsal cutaneous-to-radial amplitude ratio (MDRAR) in diabetic polyneuropathy (DP). Methods: Seventy-four patients clinically diagnosed with DP and 40 healthy controls underwent nerve conduction studies (NCS), including sural, radial, medial plantar (MP), and MDC sensory recordings. Most patients had recent-onset, mild-to-moderate DP. Sural-to-radial amplitude ratio (SRAR), medial plantar-to-radial amplitude ratio (MPRAR), and MDRAR were calculated. Minimal tibial F-wave latencies were height-corrected, and sural amplitudes were age-corrected. Diagnostic cut-off values were established by ROC analysis. Values below the cut-off, as well as absent responses, were classified as abnormal, and sensitivity and specificity were calculated. Results: A sural SNAP <6 µV demonstrated 42% sensitivity and 100% specificity. A minimal tibial F-wave latency ≥50 ms had 61% sensitivity and 100% specificity. For SRAR, a cut-off ≤0.40 yielded 49% sensitivity and 97% specificity; the 0.34 cut-off produced 38% sensitivity and 100% specificity, while the 0.21 cut-off yielded 19% sensitivity and 100% specificity. MPRAR and MDRAR demonstrated higher sensitivities (61 and 68%) but lower specificities (82 and 75%). Sural responses were obtainable in 82% of patients, whereas MP and MDC responses were recorded in 50 and 39%, respectively. Conclusions: MDRAR did not provide additional diagnostic value as a stand-alone electrophysiological parameter; however, bilateral absence of MDC responses emerged as a valuable marker of early distal involvement in DP. Further studies in selected patient groups are warranted to clarify the diagnostic contribution of MDRAR, particularly in early-stage and predominantly axonal forms of DP.